Friday, May 13, 2022
No Result
View All Result
Medical Finance
  • Home
  • News
  • Interviews
  • Mediknowledge
  • Insights From Industry
  • Thought Leaders
  • Coronavirus
  • Whitepapers
  • Home
  • News
  • Interviews
  • Mediknowledge
  • Insights From Industry
  • Thought Leaders
  • Coronavirus
  • Whitepapers
No Result
View All Result
Medical Finance
No Result
View All Result
Home Coronavirus

Study finds two doses of mRNA or ChAdOx1 vaccines provide excellent protection against severe outcomes of hospitalization and death

by Medical Finance
in Coronavirus
Study: Effectiveness of COVID-19 vaccines against hospitalization and death in Canada: A multiprovincial test-negative design study. Image Credit: Ken stocker/Shutterstock
9
SHARES
99
VIEWS
Share on FacebookShare on Twitter

In a recent study posted to the medRxiv* preprint server, the researchers assessed the effectiveness of coronavirus disease 2019 (COVID-19) vaccines against related hospitalizations and death.

Study: Effectiveness of COVID-19 vaccines against hospitalization and death in Canada: A multiprovincial test-negative design study. Image Credit: Ken stocker/Shutterstock
Study: Effectiveness of COVID-19 vaccines against hospitalization and death in Canada: A multiprovincial test-negative design study. Image Credit: Ken stocker/Shutterstock

Various studies have reported the waning efficacy of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines. Amid these reports, the effectiveness of administering heterologous COVID-19 vaccine schedules needs extensive research.

About the study

In the present study, the authors estimated the vaccine effectiveness (VE) of the BNT162b2 messenger ribonucleic acid (mRNA), the Moderna mRNA-1273, and the chimpanzee adenovirus-vectored vaccine developed by the University of Oxford-1 (ChAdOx1) vaccines against COVID-19-related hospitalizations and deaths.

The team performed a test-negative design study involving the populations residing in Quebec, Ontario, Manitoba, and British Columbia (BC) who were tested for SARS-CoV-2 infection. The eligible participants were residents aged 18 years or over, qualified to receive provincial health insurance, not a resident of long-term care institutions, and tested for COVID-19 between the date of vaccine availability and 30 September 2021.

The primary outcome of the study included COVID-19-related hospitalization or death recognized by administrative databases and/or notifiable disease reporting systems. The team defined COVID-19 hospitalization as the admission of a patient to a hospital or an intensive care unit (ICU) with a positive SARS-CoV-2 test 14 days prior or three days after hospitalization. COVID-19 death was described as death after a recent SARS-CoV-2 positive test, reported from notifiable disease reporting systems, or the incidence of death reported within 30 days of testing SARS-CoV-2 positive or within seven days of post-mortem. The team included COVID-19-related hospitalizations and deaths occurring before 30 September 2021.

Participants who reported COVID-19 hospitalizations and deaths were considered test-positive cases, while those who tested negative but presented COVID-19 symptoms were considered test-negative controls. SARS-CoV-2 lineage of the positive samples was determined via whole-genome sequencing (WGS) or screening polymerase chain reaction (PCR) tests as either SARS-CoV-2 Alpha, Beta, Gamma, Beta/Gamma, or Delta variants of concern (VOCs) or non-VOC SARS-CoV-2.

The team collected information including age, sex, residential area, two-week test periods, number of reverse-transcriptase PCR (RT-PCR) tests taken three months before the beginning of the study, high-risk comorbidities, and the receipt of influenza vaccinations in the previous years.              

Results

The study results showed that among the 2,508,296 SARS-CoV-2-tested participants, 33,420 reported severe COVID-19-related outcomes. At least one dose of a COVID-19 vaccine was received by almost 13% to 20% of the SARS-CoV-2-positive severe outcome cases and 4% to 46% of the symptomatic test-negative controls. Test positive cases were more likely to be male, older, not have tested for COVID-19 in the last three months, have a comorbidity, and have been vaccinated against influenza.

The adjusted VE (aVE) was found to be 83% against COVID-19-related hospitalization and 83% against death post the first vaccine dose, while the same increased to 98% for both the outcomes post the second dose. An increase in the aVE was also observed against severe COVID-19 outcomes of hospitalization or death from 43% zero to 13 days after the administration of the first dose to 87% 84 days after the first dose. Furthermore, aVE also improved from 93% zero to six days to 98% more than 112 days after the receipt of the second vaccine dose. For CHAdOx1 vaccinations, the aVE against severe outcomes rose from 37% zero to 13 days to 88% 56 days and more after the first dose, which further increased to 97% 56 days and more after the second dose administration.

Moreover, the aVE against COVID-19-related severe outcomes more than 14 days after the first dose was higher in individuals aged between 18 to 59 years as compared to older adults aged 80 years and more and in participants who had comorbidities versus those who did not. However, the aVE was similar for all sub-groups seven days or more after the administration of the second dose.

The aVE against COVID-19-related severe outcomes was more than 80% for over 14 days after the receipt of the first dose of mRNA-1273, BNT162b2, or ChAdOx1 vaccines. The aVE for the same outcome increased to 97% and higher more than seven days after the second vaccine dose. Notably, the aVE against severe COVID-19 outcomes was comparable seven days and more after the second dose of a ChAdOx1/mRNA mixed or mixed mRNA schedule. Moreover, aVE against COVID-19 severity caused by VOC infection was 61% against the SARS-CoV-2 Beta VOC and 89% against the Delta VOC 14 days and more after the first dose, which increased to over 97% against the Alpha, Gamma, and Delta VOCs seven days and more after the second dose.       

Conclusion

The study findings showed that two doses of mRNA or ChAdOx1 vaccines provided efficient protection against severe COVID-19 outcomes like hospitalizations and deaths before the emergence of the SARS-CoV-2 Omicron VOC. The researchers believe that the administration of homologous and heterologous vaccines could provide robust protection against COVID-19 severity.

*Important notice

medRxiv publishes preliminary scientific reports that are not peer-reviewed and, therefore, should not be regarded as conclusive, guide clinical practice/health-related behavior, or treated as established information.

Total
0
Shares
Share 0
Tweet 0
Pin it 0
Share 0
Medical Finance

Medical Finance

Related Posts

Study: Close relatives of MERS-CoV in bats use ACE2 as their functional receptors. Image Credit: Kateryna Kon / Shutterstock.com

Scientists evaluate zoonotic potential of NeoCoV, a coronavirus related to MERS-CoV

by Medical Finance
May 12, 2022
0

In a recent study published on the bioRxiv* preprint server, researchers unexpectedly identify the angiotensin-converting enzyme 2 (ACE2) as the...

Study: Should healthcare workers with SARS-CoV-2 household exposures work? A Cohort Study. Image Credit: Matteo Benegiamo / Shutterstock.com

Research evaluates whether HCWs exposed to SARS-CoV-2 at home should work

by Medical Finance
May 12, 2022
0

In a recent study published on the medRxiv* preprint server, researchers evaluate the risk of healthcare workers (HCW) becoming infected...

Study: Mutations of SARS-CoV-2 variants of concern escaping Spike-specific T cells. Image Credit: Imilian/Shutterstock

SARS-CoV-2 mutations and their impact on spike protein-specific T lymphocytes

by Medical Finance
May 12, 2022
0

A recent study posted to the bioRxiv* preprint server assessed the impact of mutations in severe acute respiratory syndrome coronavirus-2...

Study: Design of immunogens for eliciting antibody responses that may protect against SARS-CoV-2 variants. Image Credit: ktsdesign/Shutterstock

Scientists identify immunogens that can elicit antibody responses against multiple SARS-CoV-2 variants

by Medical Finance
May 12, 2022
0

In a recent paper posted to the bioRxiv* preprint server, researchers identified conserved sites in the severe acute respiratory syndrome...

Study: Early Alveolar Epithelial Cell Necrosis is a Potential Driver of ARDS with COVID-19. Image Credit: PANsight/Shutterstock

Early-stage alveolar epithelial cell necrosis linked to COVID-19-induced acute respiratory distress syndrome

by Medical Finance
May 12, 2022
0

In a study posted to the medRxiv* preprint server, an interdisciplinary team of researchers analyzed whether alveolar epithelial cell necrosis...

New mathematical model can calculate the risk of resistance evolution for drug pairs

Treating COVID with antibiotics could be a much simpler way of making people better

by Medical Finance
May 12, 2022
0

A recent study conducted in an Egyptian hospital showed that treating moderate-to-severe COVID patients with either one of two antibiotics...

Next Post
Omicron variant found to be much less sensitive to neutralizing antibodies than Delta

SARS-CoV-2 virus may be shed for much longer periods by some infected patients, study shows

AI-driven solution predicts RNA and DNA binding sites to accelerate rational drug discovery

Structural proteomics approaches can help in the treatment of neurodegenerative diseases

0 0 votes
Article Rating
Subscribe
Login
Notify of
guest
guest
0 Comments
Inline Feedbacks
View all comments

Support

  • Contact
  • Disclaimer
  • Home
  • Privacy Policy
  • Terms And Conditions

Categories

  • Coronavirus
  • Insights From Industry
  • Interviews
  • Mediknowledge
  • News
  • Thought Leaders
  • Whitepapers

More News

  • Favipiravir, lopinavir-ritonavir or combination therapy (FLARE): a randomised, double-blind, 2x2 factorial placebo-controlled trial of early antiviral therapy in COVID-19. Image Credit: Corona Borealis Studio/Shutterstock
    Trial of early antiviral therapy for COVID-19 shows no significant benefit
  • Microbiology 620x480
    Drug-resistant, pathogenic yeasts found on surfaces of apples and other fruits
  • Home
  • Privacy Policy
  • Contact
  • Disclaimer
  • Terms And Conditions

© 2022 Medical Finance - Latest Financial and Business News

No Result
View All Result
  • Interviews
  • Mediknowledge
  • News
  • Insights From Industry
  • Coronavirus
  • Thought Leaders
  • Whitepapers
wpDiscuz
0
0
Would love your thoughts, please comment.x
()
x
| Reply